D	C177536	GDC Property Terminology	C172602	Primary Tumor Site Indicator	An indication as to whether an anatomical location is the primary tumor site of disease.	diagnosis_is_primary_disease	diagnosis is primary disease	
A	C177536	GDC Property Terminology	C161319	Condition or Disease under Study	Primary disease(s) or condition(s) being studied in the trial, or the focus of the study. (clinicaltrials.gov)	diagnosis_is_primary_disease	diagnosis is primary disease	
C	C177536	GDC Property Terminology	C182116	Data Analysis Workflow URL	A URL-formatted web address for a data analysis workflow.	workflow_link	workflow link	
C	C177537	GDC Value Terminology	C156439	REPLI-g X DNA	A genomic DNA sample that has been produced by two rounds of REPLI-g amplification.	Repli-G X | experimental_protocol_type || Repli-G X (Qiagen) DNA | analyte_type || Repli-G X (Qiagen) DNA | sample_type || X | analyte_type_id	C156434 || C177560 || C177580 || C70713	analyte_type || experimental_protocol_type || analyte_type_id || sample_type
C	C177537	GDC Value Terminology	C28224	Focal	Limited to a specific area.	Focal | anaplasia_present_type	C178287	anaplasia_present_type
C	C177537	GDC Value Terminology	C122576	Staphylococcus aureus Infection	An infectious process in which the bacteria Staphylococcus aureus is present.	Staphylococcus aureus | comorbidity || Staphylococcus aureus | risk_factor	C16457 || C17103	comorbidity || risk_factor
A	C177537	GDC Value Terminology	C182456	Comma Separated Values Format	A text file format that separates data elements with commas.	CSV | data_format	C42761	data_format
C	C177537	GDC Value Terminology	C82937	MAGE-TAB	A tab-delimited, spreadsheet-based format that can be used for annotating and communicating microarray data in a MIAME (Minimum Information About a Microarray Experiment) compliant fashion.	MAGE-TAB | data_format || MAGETAB | data_format	C42761	data_format
A	C177537	GDC Value Terminology	C60763	Supplement	Textual matter that is added onto a publication or document, usually at the end; a section added to a book or document to give further information or to correct errors.	Supplementary Files | data_type	C42645	data_type
C	C177537	GDC Value Terminology	C179446	mirVana RNA Isolation	A proprietary, rapid procedure using a glass fiber filter (GFF)-based method to purify total RNA from a sample. The total RNA can then be reapplied to a second GFF to purify small RNAs (miRNAs, siRNAs, and/or snRNAs).	H | analyte_type_id || mirVana (Allprep DNA) RNA | experimental_protocol_type	C177560 || C177580	experimental_protocol_type || analyte_type_id
C	C177537	GDC Value Terminology	C172264	Buccal Cell Sample	A sample comprised of cells collected from the inside of a subject's cheek.	12 | sample_type_id || Buccal Cell Normal | sample_type || Buccal Cells | composition	C177581 || C53414 || C70713	sample_type_id || composition || sample_type
C	C177537	GDC Value Terminology	C172293	Original Tumor Cell Sample	A sample comprised of cells that were isolated from a tumor and have not been cultured or expanded.	08 | sample_type_id || Human Tumor Original Cells | sample_type	C177581 || C70713	sample_type_id || sample_type
A	C177537	GDC Value Terminology	C116938	CDK4/6 Inhibition	Inhibition of cyclin-dependent kinases 4 and 6 pathway activity to prevent proliferation of cancer cells and tumor growth.	CDK4/6 Inhibitor | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C118284	Zilovertamab	A humanized monoclonal antibody against the extracellular domain of the human receptor tyrosine kinase-like orphan receptor 1 (ROR1), with potential antineoplastic activity. Upon administration, zilovertamab binds to ROR1 and blocks ROR1-mediated signaling. This prevents tumor cell proliferation in cancer cells overexpressing ROR1. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is normally expressed during embryogenesis.  It is overexpressed in certain leukemias and solid tumors, but minimally expressed in healthy cells.	Cirmtuzumab | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C121778	Sotevtamab	A humanized, immunoglobulin (Ig) G2 monoclonal antibody against the secreted form of human clusterin (sCLU) expressed by tumor cells, with potential antineoplastic and anti-metastatic activities. Upon administration, sotevtamab specifically binds to tumor-associated sCLU and inhibits its activity. This inhibits both the sCLU-mediated signal transduction pathways and epithelial-to-mesenchymal transition (EMT), which leads to the inhibition of tumor cell migration and invasion. In addition, sotevtamab enhances chemo-sensitivity. sCLU, a heterodimeric disulfide-linked glycoprotein overexpressed by various types of cancer cells, contributes to proliferation and survival of cancer cells, and stimulates tumor cell EMT.	Anti-sCLU Monoclonal Antibody AB-16B5 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C133691	Aumolertinib	An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, aumolertinib binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, inhibits the tyrosine kinase activity of EGFR T790M, prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.	EGFR T790M Inhibitor HS-10296 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C114494	Asciminib	An orally bioavailable, allosteric Bcr-Abl1 tyrosine kinase inhibitor, with antineoplastic activity. Upon administration, asciminib targets and binds to the myristoyl pocket of the Bcr-Abl1 fusion protein at a location that is distinct from the ATP-binding domain, thereby inhibiting the activity of both wild-type Bcr-Abl and certain mutation forms, including the T315I mutation. This binding results in the inhibition of Bcr-Abl1-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies. The Bcr-Abl1 fusion protein tyrosine kinase is an abnormal enzyme produced by leukemia cells that contain the Philadelphia chromosome.	Asciminib | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C146860	Elranatamab	A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, elranatamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.	Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody PF-06863135 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C157496	Fostroxacitabine Bralpamide	A liver-targeting nucleotide phosphoramidate prodrug of troxacitabine monophosphate (TRX-MP), a dioxolane derivative and L-configuration deoxycytidine analogue, with potential antineoplastic activity. Upon oral administration, fostroxacitabine bralpamide is rapidly and specifically hydrolyzed in hepatocytes by liver carboxylesterase 1 (carboxylesterase 1, CE-1), generating high levels of the chain-terminating nucleotide, troxacitabine triphosphate (TRX-TP) in the liver. TRX-TP is then incorporated into tumor cell DNA, leading to termination of DNA synthesis and inhibition of tumor cell proliferation.	Troxacitabine Nucleotide Prodrug MIV-818 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C157493	Adagrasib	An orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration adagrasib covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.	KRAS G12C Inhibitor MRTX849 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C118672	Tasurgratinib	An inhibitor of the fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) pathway, with potential antineoplastic activity. Upon administration, tasurgratinib selectively interferes with the binding of FGF to FGFR through an as of yet not fully elucidated mechanism. This inhibits FGFR-mediated signaling and leads to both cell proliferation inhibition and cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation, and survival; its expression is upregulated in many tumor cell types.	FGF/FGFR Pathway Inhibitor E7090 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C151953	Locnartecan	A miniature drug conjugate composed of the irinotecan metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) conjugated, through a cleavable linker, to a ligand of chaperone protein heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon administration of locnartecan, the HSP90 ligand moiety targets HSP90, which allows the conjugate to penetrate, accumulate and be retained in the tumor cell. Once the linker is cleaved, the SN-38 moiety is released in a sustained manner. SN-38 then binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, which results in DNA breaks, inhibition of DNA replication and apoptosis. Compared to SN-38 alone, locnartecan preferentially targets, accumulates  and is retained in the tumor cells due to its binding to Hsp90, which results in increased concentrations of SN-38 at the tumor site. This allows sustained release of SN-38 and leads to increased and prolonged efficacy while reducing toxicity to normal, healthy tissues. Hsp90, a chaperone protein upregulated and activated in a variety of tumor cells compared to normal healthy tissue, regulates the folding, stability and degradation of many oncogenic signaling proteins.	HSP90-targeted SN-38 Conjugate PEN-866 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C138991	Flumbatinib	An orally bioavailable tyrosine kinase inhibitor, with potential antineoplastic activity. Upon administration, flumbatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the proliferation of tumor cells in which these kinases are overexpressed. Bcr-Abl fusion protein is an abnormal, constitutively active enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. c-kit, a receptor tyrosine kinase mutated and constitutively activated in certain tumors, plays a key role in tumor cell survival, proliferation, and differentiation.	Flumatinib | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C163992	Tagitanlimab	A humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tagitanlimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.	Anti-PD-L1 Monoclonal Antibody A167 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C162636	Rulonilimab	A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,rulonilimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Anti-PD-1 Monoclonal Antibody F520 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C74594	Rebemadlin	A small molecule and MDM2 (murine double minute 2) inhibitor, with potential antineoplastic activity. In cancer cells, rebemadlin antagonizes the binding of MDM2 to p53, thereby preventing MDM2-mediated p53 degradation. This results in stabilizing and activating p53-dependent cell cycle arrest and apoptosis. The protein MDM2, a negative regulator of p53 activity, is overexpressed in many cancer cell types; the tumor suppressor p53 is mutated or deleted in about 50% of all cancers but active in the other 50%.	Nutlin-3a | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C168617	Tifcemalimab	A recombinant humanized immunoglobulin G4 kappa (IgG4k) monoclonal antibody directed against B- and T-lymphocyte attenuator (BTLA), with potential immunomodulating and antineoplastic activities. Upon intravenous infusion administration, tifcemalimab targets and binds to BTLA. This prevents BTLA-mediated inhibition of T-cell activation leading to antigen specific T-cell proliferation and activation of a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. BTLA, an immunoglobulin (Ig) receptor family member expressed on activated T- and B- lymphocytes, subsets of dendritic cells (DCs), macrophages, and nature killer (NK) cells, is an immune checkpoint involved in suppressing immune responses. It mediates inhibition of human tumor-specific CTLs upon engagement by tumor expressed herpesvirus-entry mediator (HVEM).	Anti-BTLA Monoclonal Antibody TAB004 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C135632	Vixtimotamab	An anti-CD33/anti-CD3 bispecific tetravalent antibody, with potential immunostimulatory and antineoplastic activities. Anti-CD33/CD3 tetravalent bispecific monoclonal antibody AMV564 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD33, a tumor-associated antigen (TAA) overexpressed on the surface of a variety of tumor cell types. Upon infusion of vixtimotamab, this bispecific antibody binds to CD3-expressing T-cells and CD33-expressing tumor cells, thereby crosslinking CD33-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD33-expressing cells. CD33, a glycoprotein expressed by a variety of cancers, including the majority of acute myeloid leukemias (AMLs), and normal non-pluripotent hematopoietic stem cells, plays a key role in tumor initiation, proliferation and progression.	Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C99123	Sirexatamab	A humanized monoclonal antibody directed against the WNT antagonist dickkopf homolog 1 (DKK1), with potential anti-osteolytic activity. Upon administration, sirexatamab binds to and inhibits DKK1, thereby restoring signaling through the WNT pathway, which may result in osteoblast differentiation and activation within the bone matrix and the reversal of tumor-induced osteolytic disease. DKK1, overexpressed by certain cancer cells, is an inhibitor of the WNT signaling pathway and prevents the mediated formation of bone.	Anti-DKK-1 Monoclonal Antibody LY2812176 | therapeutic_agents || DKK1-Neutralizing Monoclonal Antibody DKN-01 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C159530	Pavunalimab	An Fc-engineered bispecific antibody directed against the human negative immunoregulatory checkpoint receptors cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) and lymphocyte activation gene 3 protein (LAG3; LAG-3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, bavunalimab targets and binds to both CTLA-4 and LAG-3 expressed on T-cells in the tumor microenvironment (TME). Both CTLA-4 and LAG-3 are inhibitory receptors and members of the immunoglobulin superfamily (IgSF); they are overexpressed by regulatory T-cells (Tregs) in the TME where they downregulate T-cell activation and proliferation. Dual checkpoint blockade of CTLA-4 and LAG-3 with XmAb22841 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. The engineered Fc domain increases the stability and half-life of the antibody.	Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C129653	Sotuletinib	An orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF-1R; CSF1R), with potential antineoplastic activity. CSF1R inhibitor BLZ945 selectively binds to CSF1R expressed on tumor-associated macrophages (TAMs), blocks the activity of CSF1R, and inhibits CSF1R-mediated signal transduction pathways. This inhibits the activity and proliferation of TAMs, and reprograms the immunosuppressive nature of existing TAMs. Altogether, this reduces TAM-mediated immune suppression in the tumor microenvironment, re-activates the immune system, and improves anti-tumor cell responses mediated by T-cells.  CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor for its ligand, colony stimulating factor 1 (CSF1); this receptor is overexpressed by TAMs in the tumor microenvironment, and plays a major role in both immune suppression and the induction of tumor cell proliferation.	CSF-1R Inhibitor BLZ945 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C153379	Cadonilimab	A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cadonilimab targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with cadonilimab may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.	Anti-PD-1/CTLA-4 Bispecific Antibody AK104 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C158085	Bafisontamab	A human, Fabs-in-tandem immunoglobulin (FIT-Ig)-based, tetravalent, bispecific antibody targeting both the epidermal growth factor receptor EGFR and the hepatocyte growth factor receptor (HGFR;; cMet; c-Met), with potential antineoplastic activity. Upon administration, bafisontamab simultaneously targets and binds to wild-type or certain mutant forms of both EGFR and c-Met expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and c-Met-mediated signaling pathways and results in the inhibition of tumor cell proliferation. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation. In bafisontamab, the two antigen-binding fragments (Fabs) are fused directly in a crisscross orientation resulting in four active and independent antigen binding sites.	Anti-EGFR/c-Met Bispecific Antibody EMB-01 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C173664	Rucosopasem Manganese	A mimetic of the enzyme superoxide dismutase (SOD) that may potentially be used to increase the anti-cancer efficacy of stereotactic body radiation therapy (SBRT). Upon administration, rucosopasem manganese may mimic native SODs and catalyze the formation of molecular oxygen and hydrogen peroxide from the burst of superoxide anion present in the irradiated tissues upon radiation. As hydrogen peroxide is less toxic than superoxide to normal tissues, but more toxic to cancer cells, this may increase the anti-cancer efficacy of SBRT and decrease its damage to normal tissues.	Superoxide Dismutase Mimetic GC4711 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C153129	Ubamatamab	A bispecific, human monoclonal antibody with potential antineoplastic activity. REGN4018 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen that is part of the T cell receptor complex, and one for human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303), a member of the mucin family of glycoproteins that is overexpressed by several epithelial cancers, including ovarian cancer. Upon administration, ubamatamab binds to both T-cells and MUC16-expressing tumor cells, which cross-links the T-cells to the tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against the MUC16-expressing tumor cells.	Anti-MUC16/CD3 BiTE Antibody REGN4018 | therapeutic_agents || Anti-MUC16/CD3 Bispecific Antibody REGN4018 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C105401	Idroxioleic Acid	An orally bioavailable, synthetic analog of the fatty acid oleic acid, with potential antitumor activity. Upon administration,idroxioleic acid activates sphingomyelin synthase (SMS), thereby increasing the concentration of sphingomyelin (SM) and diacylglycerol (DAG) in the tumor cell membrane and decreasing membrane levels of phosphatidylethanolamine (PE) and phosphatidylcholine (PC). This restores the normal, healthy levels and ratios of membrane lipids. By restoring normal membrane lipid structure and composition, this agent inhibits membrane-protein associated signaling and the aberrant activity of signaling pathways in certain tumor cells, including the Ras/MAPK and PI3K/AKt pathways. This inhibits tumor cell proliferation, induces tumor cell differentiation, and eventually can cause cell death.	2-Hydroxyoleic Acid | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C123915	Eramkafusp Alfa	A humanized monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20 and fused to the recombinant cytokine, interferon-alpha (IFN-a), with potential antineoplastic and immunomodulating activities. Upon administration of eramkafusp alfa, the antibody moiety specifically targets and binds to CD20. In turn, the IFN-a moiety binds to the IFN receptor, and activates IFN-mediated signal transduction, which induces the transcription and translation of genes whose protein products mediate anticancer effects. This results in the induction of both G2 cell cycle arrest and apoptosis in CD20-expressing tumor cells. In addition, IGN002 causes the induction of complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies.	Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C157242	Surzebiclimab	A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, surzebiclimab binds to TIM-3 expressed on certain T-cells, including tumor-infiltrating lymphocytes (TILs), thereby preventing the engagement of TIM-3 by its ligands, phosphatidylserine (PtdSer) and galectin-9. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.	Anti-TIM-3 Monoclonal Antibody BGB-A425 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C158517	Sabizabulin	An orally bioavailable, small molecule tubulin inhibitor, with potential antineoplastic, antiviral and anti-inflammatory activities. Upon oral administration, sabizabulin binds to the colchicine-binding site of alpha- and beta-tubulin subunits of microtubules and crosslinks the microtubules, thereby inhibiting microtubule polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature, tumor blood flow, deprives tumor cells of nutrients, and induces apoptosis. In addition, as microtubules plays an important role in intracellular transport, the inhibition of its polymerization may disrupt the transport of the androgen receptor (AR) into the cell nucleus, as well as virus trafficking around the cell. This may decrease viral replication and assembly. Inhibition of tubulin polymerization may also inhibit the release of pro-inflammatory cytokines and disrupt inflammatory cell activities. Sabizabulin is not a substrate of P-glycoprotein (Pgp), an efflux pump that when overexpressed, may confer resistance to taxane agents.	Tubulin Polymerization Inhibitor VERU-111 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C90539	Mipicoledine	A cholesterol carbonate derivative of 4-demethylpenclomedine (DM-PEN) with potential antineoplastic alkylating activity. Upon intravenous administration of mipicoledine, the carbonium moiety binds to and alkylates DNA at the N7 guanine position, thereby causing DNA crosslinks. This prevents DNA replication, inhibits cellular proliferation and triggers apoptosis. In addition, due to its lipophilic cholesteryl moiety this agent is able to cross the blood brain barrier (BBB) and therefore can be given intravenously compared to other alkylating agents that need to be given intra-cranially.	DM-CHOC-PEN | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C116624	Navtemadlin	An orally available inhibitor of MDM2 (murine double minute 2), with potential antineoplastic activity. Upon oral administration,navtemadlin binds to the MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it plays a key role in cancer cell proliferation and survival.	MDM2 Inhibitor AMG-232 | therapeutic_agents || MDM2 Inhibitor KRT-232 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C166238	Non-Tumor Tissue Area	The area within a sample that is represented by non-tumor tissue.	Non cancerous tissue | tumor_code	C177615	tumor_code
C	C177537	GDC Value Terminology	C4798	Recurrent Neoplasm	The reemergence of a neoplasm after a period of remission.	02 | sample_type_id || Recurrence | tumor_descriptor || Recurrent Tumor | sample_type || recurrence | classification_of_tumor	C166229 || C174459 || C177581 || C70713	tumor_descriptor || classification_of_tumor || sample_type_id || sample_type
C	C177537	GDC Value Terminology	C8509	Primary Neoplasm	A tumor at the original site of origin.	01 | sample_type_id || Primary | tumor_descriptor || Primary Tumor | sample_type || primary | classification_of_tumor	C166229 || C174459 || C177581 || C70713	tumor_descriptor || classification_of_tumor || sample_type_id || sample_type